CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Conventional treatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug57 ACEIs Wiki 0.71
drug288 BDB-001 Injection Wiki 0.71
drug2724 [TIMP-2]*[IGFBP-7] Wiki 0.71

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D058186 Acute Kidney Injury NIH 0.17
D011014 Pneumonia NIH 0.04

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.17
HP:0002090 Pneumonia HPO 0.04

There are 2 clinical trials

Clinical Trials


1 Randomized Trial of ACEIs in Treatment of COVID-19

ACEIs as treatment for COVID19

NCT04345406 COVID Drug: ACEIs Drug: Conventional treatment

Primary Outcomes

Description: number of patients with virological cure

Measure: number of patients with virological cure

Time: 6 months

2 A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III

This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001 injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome. Patients will be randomized to two treatment arms (Arm A: Conventional treatment + BDB-001; Arm B: Conventional treatment alone).

NCT04449588 COVID-19 Pneumonia Drug: BDB-001 Injection Other: Conventional treatment
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Measure: Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline

Time: Baseline to Day 28

Measure: 28-day all-cause mortality rate

Time: Baseline to Day 28

Secondary Outcomes

Measure: Percentage of subjects achieving recovery in SpO2

Time: Baseline to Day 28

Measure: Mean change of PaO2/FiO2

Time: Baseline to Day 28

Measure: Mechanical ventilation time

Time: Baseline to Day 28

Measure: Time of oxygen therapy

Time: Baseline to Day 28

Measure: Lymphocyte count

Time: Baseline to Day 28

Measure: Change in inflammation indicators (CRP or IL-6) from baseline

Time: Baseline to Day 28

Measure: Improvement in body temperature

Time: Baseline to Day 28

Measure: Mean change from baseline in the clinical improvement based on ordinal scale recommended by the WHO R&D Blueprint during treatment period

Time: Baseline to Day 28

Measure: Improvement at Day3, 7, 11 & Day14 based on ordinal scale recommended by the WHO R&D Blueprint during treatment period

Time: Baseline, Day 3, Day 7, Day 11, Day 14

Measure: Time to get categories 1 to 4 in the 8-points ordinal scale

Time: Baseline to Day 28

Measure: Time to attain an improvement of 1 point on the ordinal scale

Time: Baseline to Day 28


Related HPO nodes (Using clinical trials)